Overview
- Eli Lilly is preparing a €15 billion proposal for French biotech Abivax and has not submitted a formal bid as it seeks regulatory clarity in France.
- Tirzepatide generated $24.8 billion in the first nine months of 2025, surpassing Keytruda as the top-selling medicine and adding an approval for obstructive sleep apnea.
- Orforglipron, Lilly’s oral weight-loss candidate, is under expedited review with a company-expected approval decision by the end of February 2026.
- Retatrutide delivered a 28.7% mean weight loss at the highest dose in phase 3, a level not previously seen in the field.
- Competition is intensifying as Novo Nordisk secured approval for the first oral weight-loss pill and Amgen and Pfizer advance rival programs.